Literature DB >> 18690513

Intracerebral haemorrhage in primary and metastatic brain tumours.

Andrea Salmaggi1, Alessandra Erbetta, Antonio Silvani, Emanuela Maderna, Bianca Pollo.   

Abstract

Intracerebral haemorrhage may both be a presenting manifestation in unrecognised brain tumour or--more frequently--take place in the disease course of known/suspected brain tumour due to diagnostic/therapeutic procedures, including biopsy, locoregional treatments and anti-angiogenic therapies. Apart from the difficulties inherent to accurate neuroradiological diagnosis in selected cases with small tumour volume, the main clinical problem that neurologists face is represented by decision making in prophylaxis/treatment of venous thromboembolism in these patients. These points are briefly discussed and available evidence on the last point is commented on.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690513     DOI: 10.1007/s10072-008-0958-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

1.  Management of thrombosis in a neuro-oncology patient.

Authors:  Nancy Eisenson
Journal:  Oncol Nurs Forum       Date:  2007-07       Impact factor: 2.172

2.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

Review 3.  Significance of hemorrhage into brain tumors: clinicopathological study.

Authors:  D Kondziolka; M Bernstein; L Resch; C H Tator; J F Fleming; R G Vanderlinden; H Schutz
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

4.  Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

Authors:  Ian F Pollack; Regina I Jakacki; Susan M Blaney; Michael L Hancock; Mark W Kieran; Peter Phillips; Larry E Kun; Henry Friedman; Roger Packer; Anu Banerjee; J Russell Geyer; Stewart Goldman; Tina Young Poussaint; Matthew J Krasin; Yanfeng Wang; Michael Hayes; Anthony Murgo; Susan Weiner; James M Boyett
Journal:  Neuro Oncol       Date:  2007-02-09       Impact factor: 12.300

5.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

6.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

7.  Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.

Authors:  Alberto Broniscer; Fred H Laningham; Mehmet Kocak; Matthew J Krasin; Maryam Fouladi; Thomas E Merchant; Larry E Kun; James M Boyett; Amar Gajjar
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

  7 in total
  1 in total

1.  Intra-tumoral hemorrhage: A potential problem for all types and grades of intracranial neoplasms.

Authors:  Roger W Byard
Journal:  Surg Neurol Int       Date:  2012-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.